Investigational bispecific monoclonal antibody that binds glypican-3 (GPC3) on tumor cells and delivers 4-1BB (CD137) costimulation to T cells to locally activate anti-tumor immunity (IV).
Bispecific antibody that binds GPC3 on tumor cells and 4-1BB (CD137) on activated T cells (and NK cells), crosslinking them to deliver local 4-1BB costimulation in the tumor microenvironment, thereby enhancing cytotoxic lymphocyte activity and lysis of GPC3-expressing tumor cells.
YES
DIRECT
The bispecific crosslinks GPC3 on tumor cells with 4-1BB on T/NK cells, delivering local 4-1BB costimulation; the engaged cytotoxic lymphocytes then kill GPC3+ cells via perforin/granzyme-mediated lysis.
Investigational bispecific monoclonal antibody that binds glypican-3 (GPC3) on tumor cells and delivers 4-1BB (CD137) costimulation to T cells to locally activate anti-tumor immunity (IV).
Bispecific antibody that binds GPC3 on tumor cells and 4-1BB (CD137) on activated T cells (and NK cells), crosslinking them to deliver local 4-1BB costimulation in the tumor microenvironment, thereby enhancing cytotoxic lymphocyte activity and lysis of GPC3-expressing tumor cells.
NO
INDIRECT
BGB-B2033 binds 4-1BB on T/NK cells and GPC3 on tumor cells to deliver 4-1BB costimulation, activating cytotoxic lymphocytes that kill GPC3+ tumor cells; 4-1BB–expressing cells themselves are not killed.
A HER2-targeted antibody–drug conjugate linking the anti-HER2 antibody disitamab to the microtubule inhibitor monomethyl auristatin E (MMAE) via a cleavable linker; upon HER2 binding and internalization, MMAE is released to disrupt microtubules, causing G2/M arrest and apoptosis with a potential bystander effect.
HER2-targeted antibody–drug conjugate linking disitamab to the microtubule inhibitor MMAE via a cleavable linker; upon HER2 binding and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing microtubule disruption, G2/M arrest, and apoptosis, with a potential bystander effect.
NO
INDIRECT
The ADC binds HER2 on target cells, is internalized, and releases MMAE, which inhibits beta-tubulin polymerization causing microtubule disruption, G2/M arrest, and apoptosis; killing is determined by HER2 expression, not beta-tubulin.
Autologous 'armored' chimeric antigen receptor T-cell therapy targeting glypican-3 (GPC3); genetically modified T cells with CD3ζ and co-stimulatory domains designed to enhance activation, persistence, and cytotoxicity against GPC3-positive hepatocellular carcinoma.
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds glypican-3 (GPC3) on hepatocellular carcinoma cells. CAR engagement activates CD3ζ and co-stimulatory signaling, driving T-cell proliferation, cytokine release, and targeted cytotoxic killing of GPC3-positive tumor cells. The “armored” design enhances activation, persistence, and function within the immunosuppressive tumor microenvironment.
YES
DIRECT
CAR engagement of GPC3 on target cells activates T-cell CD3ζ/co-stimulatory signaling, forming an immunologic synapse and inducing cytolysis via perforin/granzyme release (and death-receptor pathways), killing GPC3-positive cells.
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy in which a patient’s tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor neoantigens via TCR–MHC and mediate cytotoxic CD8+ activity against cancer cells.
Autologous tumor-infiltrating T cells are isolated from the patient’s tumor, expanded ex vivo, and reinfused to recognize tumor neoantigens via native TCR–MHC interactions, leading to cytotoxic CD8+ T-cell–mediated killing of cancer cells and cytokine-driven antitumor activity.
YES
DIRECT
Patient-derived TILs recognize the neoantigen–HLA class I complex via their native TCR and directly kill the target cell through cytotoxic CD8+ T-cell mechanisms (perforin/granzyme and Fas–FasL–mediated apoptosis).